TABLE 2.
Correlation between FDG-SUVmax and tumor marker expression and pathologic stage in all patients with NSCLC (n = 149), lung adenocarcinoma (n = 68), and squamous carcinoma (n = 64)
| All NSCLC specimens |
Adenocarcinoma |
Squamous |
||||
|---|---|---|---|---|---|---|
| Correlation coefficient | P value | Correlation coefficient | P value | Correlation coefficient | P value | |
| Greatest tumor dimension | 0.56 | <.0001 | 0.36 | .002 | 0.63 | <.0001 |
| T classfication | 0.38 | <.0001 | 0.28 | .02 | 0.42 | .0005 |
| N classification | 0.25 | .002 | 0.26 | .03 | 0.17 | .18 |
| GLUT-1 intensity | 0.36 | <.0001 | 0.38 | .001 | 0.10 | .42 |
| GLUT-1 percent | 0.36 | <.0001 | 0.47 | <.0001 | 0.07 | .56 |
| GLUT-1 product | 0.37 | <.0001 | 0.46 | <.0001 | 0.07 | .56 |
| p53 intensity | 0.10 | .20 | 0.26 | .03 | −0.14 | .23 |
| p53 percent | 0.11 | .16 | 0.23 | .06 | −0.05 | .66 |
| p53 product | 0.12 | .14 | 0.25 | .04 | −0.09 | .50 |
| EGFR intensity | 0.20 | .01 | 0.12 | .32 | 0.18 | .14 |
| EGFR percent | 0.24 | .003 | 0.17 | .16 | 0.19 | .12 |
| EGFR product | 0.23 | .004 | 0.15 | .21 | 0.19 | .12 |
| Cyclin D1 intensity | −0.06 | .46 | 0.03 | .79 | −0.009 | .94 |
| Cyclin D1 percent | −0.13 | .11 | −0.019 | .87 | −0.07 | .57 |
| Cyclin D1 product | −0.12 | .13 | −0.03 | .79 | −0.05 | .69 |
| VEGF intensity | 0.02 | .79 | 0.21 | .08 | −0.13 | .31 |
| VEGF percent | 0.03 | .66 | 0.21 | .08 | −0.11 | .34 |
| VEGF product | 0.04 | .58 | 0.24 | .06 | −0.04 | .38 |
GLUT-1, Glucose transporter 1; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor.